Xavier Thomas

27.9k total citations · 1 hit paper
414 papers, 11.9k citations indexed

About

Xavier Thomas is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Molecular Biology. According to data from OpenAlex, Xavier Thomas has authored 414 papers receiving a total of 11.9k indexed citations (citations by other indexed papers that have themselves been cited), including 275 papers in Hematology, 151 papers in Public Health, Environmental and Occupational Health and 101 papers in Molecular Biology. Recurrent topics in Xavier Thomas's work include Acute Myeloid Leukemia Research (209 papers), Acute Lymphoblastic Leukemia research (150 papers) and Chronic Myeloid Leukemia Treatments (76 papers). Xavier Thomas is often cited by papers focused on Acute Myeloid Leukemia Research (209 papers), Acute Lymphoblastic Leukemia research (150 papers) and Chronic Myeloid Leukemia Treatments (76 papers). Xavier Thomas collaborates with scholars based in France, United States and Belgium. Xavier Thomas's co-authors include Hervé Dombret, Emmanuel Raffoux, Françoise Huguet, E Archimbaud, D Fière, Pierre Fenaux, Stéphane de Botton, Claude Preudhomme, Véronique Lhéritier and Sylvie Castaigné and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Xavier Thomas

408 papers receiving 11.6k citations

Hit Papers

Multicenter, Randomized, ... 2012 2026 2016 2021 2012 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
    2012 818 citations Hagop M. Kantarjian, Xavier Thomas et al. Journal of Clinical Oncology profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Xavier Thomas 7.4k 4.3k 3.9k 2.6k 1.7k 414 11.9k
David Ginsburg 6.7k 0.9× 844 0.2× 4.1k 1.0× 1.1k 0.4× 1.8k 1.1× 440 16.0k
Michael Kneba 2.3k 0.3× 1.8k 0.4× 991 0.3× 2.3k 0.9× 3.5k 2.0× 216 8.1k
Jae H. Park 993 0.1× 910 0.2× 1.6k 0.4× 3.7k 1.4× 370 0.2× 226 6.9k
Olivier Bernard 5.2k 0.7× 2.3k 0.5× 8.7k 2.2× 4.0k 1.6× 2.8k 1.6× 448 21.9k
Wolfgang E. Berdel 7.3k 1.0× 1.5k 0.4× 11.3k 2.9× 5.1k 2.0× 2.5k 1.4× 502 21.3k
Ronald L. Nagel 2.9k 0.4× 747 0.2× 2.2k 0.5× 219 0.1× 4.5k 2.6× 211 8.2k
Martin Fleisher 859 0.1× 248 0.1× 3.4k 0.9× 4.5k 1.8× 962 0.6× 240 12.4k
Xiao‐Jun Huang 14.0k 1.9× 4.0k 0.9× 4.6k 1.2× 5.7k 2.2× 2.9k 1.7× 1.3k 23.3k
Giuseppe Leone 6.6k 0.9× 1.4k 0.3× 4.4k 1.1× 2.6k 1.0× 3.8k 2.2× 604 16.2k
Kenneth G. Mann 14.9k 2.0× 298 0.1× 5.6k 1.4× 1.7k 0.7× 4.5k 2.6× 410 27.4k

Countries citing papers authored by Xavier Thomas

Since Specialization
Citations

This map shows the geographic impact of Xavier Thomas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xavier Thomas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xavier Thomas more than expected).

Fields of papers citing papers by Xavier Thomas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xavier Thomas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xavier Thomas. The network helps show where Xavier Thomas may publish in the future.

Co-authorship network of co-authors of Xavier Thomas

This figure shows the co-authorship network connecting the top 25 collaborators of Xavier Thomas. A scholar is included among the top collaborators of Xavier Thomas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xavier Thomas. Xavier Thomas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thomas, Xavier. (2025). Examining the safety and efficacy of imetelstat in low-risk myelodysplastic syndrome. Expert Opinion on Pharmacotherapy. 26(5). 525–533. 1 indexed citations
2.
Hirsch, Pierre, Jérôme Lambert, Maxime Bucci, et al.. (2024). Multi-target measurable residual disease assessed by error-corrected sequencing in patients with acute myeloid leukemia: An ALFA study. Blood Cancer Journal. 14(1). 97–97. 3 indexed citations
3.
Pleșa, Adriana, Gaëlle Fossard, Fiorenza Barraco, et al.. (2022). Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study. Transplantation and Cellular Therapy. 29(1). 38.e1–38.e9. 4 indexed citations
4.
Touzart, Aurore, Étienne Lengliné, Mohamed Belhocine, et al.. (2019). Epigenetic Silencing Affects l -Asparaginase Sensitivity and Predicts Outcome in T-ALL. Clinical Cancer Research. 25(8). 2483–2493. 28 indexed citations
5.
Maréchal, Marion Le, Hélène Labussière‐Wallet, Sophie Ducastelle-Leprêtre, et al.. (2018). Chronic disseminated candidiasis and acute leukemia: Impact on survival and hematopoietic stem cell transplantation agenda. Médecine et Maladies Infectieuses. 48(3). 202–206. 4 indexed citations
6.
He, Jianming, et al.. (2017). Patient-Reported Disease Burden in the Elderly Patients with Acute Myeloid Leukemia. Blood. 130. 2182–2182. 2 indexed citations
7.
8.
9.
Thomas, Xavier, et al.. (2016). The safety of treatment options for elderly people with acute myeloid leukemia. Expert Opinion on Drug Safety. 15(5). 635–645. 2 indexed citations
10.
Bally, Cécile, Jehane Fadlallah, Guy Leverger, et al.. (2012). Outcome of Acute Promyelocytic Leukemia (APL) in Children and Adolescents: An Analysis in Two Consecutive Trials of the European APL Group. Journal of Clinical Oncology. 30(14). 1641–1646. 32 indexed citations
11.
Kantarjian, Hagop M., Xavier Thomas, Anna Dmoszyńska, et al.. (2012). Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia. Journal of Clinical Oncology. 30(21). 2670–2677. 818 indexed citations breakdown →
12.
Thomas, Xavier, Youcef Chelghoum, Giovanna Cannas, et al.. (2011). Leukocytosis and Circulating Blasts in Older Adults With Newly Diagnosed Acute Myeloid Leukemia: Are They Valuable Factors for Therapeutic Decision-Making?. Clinical Lymphoma Myeloma & Leukemia. 11(4). 342–349. 7 indexed citations
13.
Thomas, Xavier. (2007). [Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].. PubMed. 94(10). 871–80. 1 indexed citations
14.
15.
Thomas, Xavier & Quoc‐Hung Le. (2003). Stratégies thérapeutiques actuelles dans les leucémies aiguës lymphoblastiques de l‘adulte. Bulletin du Cancer. 90(10). 833–850. 3 indexed citations
16.
Thomas, Xavier & Quoc‐Hung Le. (2002). Traitement des leucémies aiguës myéloïdes de l'adulte en rechute. Bulletin du Cancer. 89(9). 795–807. 1 indexed citations
17.
Dhédin, Nathalie, Xavier Thomas, F. Huguet, et al.. (2002). No Superiority of Autologous Stem Cell Transplantation over Chemotherapy Alone in Adult Ph-Negative ALL in First Complete Remission A Long Follow-Up Report Combining Results of LALA 85, 87 and 94 Trials. Blood. 100(11). 81516. 2 indexed citations
18.
Charrin, C, Nicole Dastugue, M Jotterand-Bellomo, et al.. (2002). Prospective, karyotype analysis in adult acute lymphoblastic leukemia: A LALA group (French-Belgium-Switzerland) report of 730 cases. Blood. 100(11). 2 indexed citations
19.
Thomas, Xavier, et al.. (2002). Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Annals of Hematology. 81(9). 504–507. 56 indexed citations
20.
Thomas, Xavier, Bruno Anglaret, Jean‐Pierre Magaud, Joshua Epstein, & E Archimbaud. (1998). Interdependence between Cytokines and Cell Adhesion Molecules to Induce Interleukin-6 Production by Stromal Cells in Myeloma. Leukemia & lymphoma. 32(1-2). 107–119. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David Ginsburg Breakdown of academic impact, for papers by Michael Kneba Breakdown of academic impact, for papers by Jae H. Park Breakdown of academic impact, for papers by Olivier Bernard Breakdown of academic impact, for papers by Wolfgang E. Berdel Breakdown of academic impact, for papers by Ronald L. Nagel Breakdown of academic impact, for papers by Martin Fleisher Breakdown of academic impact, for papers by Xiao‐Jun Huang Breakdown of academic impact, for papers by Giuseppe Leone Breakdown of academic impact, for papers by Kenneth G. Mann
Rankless by CCL
2026